On Apr. 11, 2025, the UK National Institute for Health and Care Excellence (NICE) recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

NICE has published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately through the Cancer Drugs Fund.

The final draft guidance recommends capivasertib with fulvestrant for people with hormone receptor (HR)-positive HER2-negative breast cancer that has 1 or more PIK3CA, AKT1 or PTEN gene alterations and has spread within the breast tissue (locally advanced) or to other parts of the body (metastatic).

Given as a twice-a-day tablet, capivasertib is a targeted treatment called a kinase inhibitor. It works by blocking the action of an abnormal protein that tells cancer cells to multiply. This helps slow or stop the spread of cancer cells. Results from a clinical trial showed that capivasertib plus fulvestrant increased the time before the cancer got worse by around 4.2 months compared with placebo plus fulvestrant.

Hormone receptor (HR)-positive HER2-negative advanced breast cancer is incurable and the aim of treatment is to delay it getting worse and extend how long people live. If the cancer has alterations in the PIK3CA, AKT1 or PTEN genes, outcomes appear to be worse.